ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 531

Immune Responses to Mycobacterium Heat Shock Protein 70 Accompany Self-Reactivity to Human Bip in Rheumatoid Arthritis

Hirofumi Shoda1, Shuji Sumitomo1, Keishi Fujio2 and Kazuhiko Yamamoto1, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Allergy and Rheumatology,Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: heat-shock proteins, molecular mimicry, mycobacterium and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Molecular mimicry is believed to be an important mechanism of autoimmunity development. We previously demonstrated that imbalance between effector and regulatory T cells specific for BiP, a member of heat shock protein 70 family, induced autoimmne responses in rheumtaoid arthritis (RA). However, the reason why BiP-specific effector T cells developed in RA remains unclear. Here, we examined the immunological linkages between human heat shock proteins (HSPs) and Mycobacterium (Myc) HSPs in RA because the sequences of HSPs are preserved through the species.

Methods: Serum antibodies to bacteria (Mycobacterium and E.Coli) and human HSPs (HSP10, HSP40, HSP60, HSP70) in RA were measured by ELISA. Proliferation of peripheral blood mononuclear cells (PBMCs) from HLA-DR4-positive RA patients in response to MycHSP70-derived and BiP-derived peptides was examined using 3H-thymidine uptake. The effect of immunity on MycHSP70, was evaluated by immunizing HLA-DR4-trangenic mice with MycHSP70 and CFA, and measuring serum antibodies by ELISA. CD4+ T cell proliferation in response to MycHSP70 and BiP epitopes was measured by 3H-thymidine uptake. MycHSP70-derived peptide was orally administered to collagen-induced arthritis (CIA) and scores were observed.

Results:  Serum titers of antibodies against MycHSP70 were significantly elevated in RA patients and correlated with serum anti-BiP and anti-ciurullinated BiP antibody titers. A MycHSP70-derived HLA-DR4 major epitope was identified using proliferative capasity of RA PBMCs as an indicator. The major T-cell epitope, MycHSP70287-306, was located at the corresponding position in the major epitope for human BiP336-355, and PBMC proliferations in response to MycHSP70287-306 and BiP336-355 were highly correlated. These two peptides shared the common amino acid sequences which were important for HLA-DR4 binding. Immunization with MycHSP70 induced BiP-specific T cell proliferation, and development of anti-BiP antibodies. Moreover, oral administration of MycHSP70287-306resulted in amelioration of CIA and inhibition of BiP and collagen-specific T cell proliferations .

Conclusion: Immune responses to MycHSP70 were associated with adaptive immunity against BiP in RA. Mycobacterium exposure in the daily environment could trigger the immune responses. Further examination of the immune response against BiP could reveal a mechanism for the development of related autoantibodies including ACPA upon exposure to a certain spectrum of microbes.


Disclosure: H. Shoda, None; S. Sumitomo, None; K. Fujio, Astellas, BMS, Daiichi-Sankyo, MitsubishiTanabe, Pfizer, Santen, Takeda, Chugai, Eisai, Taisho Toyama, UCB, and Janssen., 2; K. Yamamoto, Boehringer Ingelheim, UCB, Eisai, Toyoma-chemical, Pfizer, Taisho Toyama, 5,Boehringer Ingelheim, Astellas, AbbVie, Eisai, Pfizer, Bristol-Myers, Janssen, UCB, Asahikasei, Santen, Ono, Taisho Toyama, Daiichisankyo, Chugai, Mitsubishi Tanabe, Eli Lilly Japan, Nipponkayaku, Takeda, 8,Immunofuture, 1,Immunofuture, 6,Astellas, TEIJIN, Bristol-Myers, Pfizer, AbbVie, Daiichisankyo, Nipponkayaku, Chugai, Mitsubishi Tanabe, Janssen, Eisai, Santen, 2.

To cite this abstract in AMA style:

Shoda H, Sumitomo S, Fujio K, Yamamoto K. Immune Responses to Mycobacterium Heat Shock Protein 70 Accompany Self-Reactivity to Human Bip in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/immune-responses-to-mycobacterium-heat-shock-protein-70-accompany-self-reactivity-to-human-bip-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immune-responses-to-mycobacterium-heat-shock-protein-70-accompany-self-reactivity-to-human-bip-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology